MX357392B - Ensayos basados en interrogatorios celulares y uso de los mismos. - Google Patents

Ensayos basados en interrogatorios celulares y uso de los mismos.

Info

Publication number
MX357392B
MX357392B MX2014011797A MX2014011797A MX357392B MX 357392 B MX357392 B MX 357392B MX 2014011797 A MX2014011797 A MX 2014011797A MX 2014011797 A MX2014011797 A MX 2014011797A MX 357392 B MX357392 B MX 357392B
Authority
MX
Mexico
Prior art keywords
based assays
interrogatory
cell
interrogatory cell
cancer
Prior art date
Application number
MX2014011797A
Other languages
English (en)
Other versions
MX2014011797A (es
Inventor
Rajin Narain Niven
Sarangarajan Rangaprasad
K Vishnudas Vivek
Du Min
Walshe Tony
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2014011797A publication Critical patent/MX2014011797A/es
Publication of MX357392B publication Critical patent/MX357392B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Abstract

La presente invención se refiere a un descubrimiento de Tecnología de Plataforma para analizar un sistema biológico o proceso (por ejemplo, un padecimiento de enfermedad, tal como cáncer) mediante la construcción de un modelo.
MX2014011797A 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y uso de los mismos. MX357392B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261619326P 2012-04-02 2012-04-02
US201261620305P 2012-04-04 2012-04-04
US201261665631P 2012-06-28 2012-06-28
US201261668617P 2012-07-06 2012-07-06
US201261678596P 2012-08-01 2012-08-01
US201261678590P 2012-08-01 2012-08-01
PCT/US2012/054321 WO2013151577A1 (en) 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof

Publications (2)

Publication Number Publication Date
MX2014011797A MX2014011797A (es) 2014-12-10
MX357392B true MX357392B (es) 2018-07-06

Family

ID=49235335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011797A MX357392B (es) 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y uso de los mismos.

Country Status (14)

Country Link
US (2) US10061887B2 (es)
EP (1) EP2834366A4 (es)
JP (3) JP6189926B2 (es)
KR (2) KR102149070B1 (es)
CN (3) CN108048521B (es)
AU (2) AU2012376214B2 (es)
BR (1) BR112014024537A2 (es)
CA (1) CA2869296A1 (es)
EA (1) EA038600B1 (es)
HK (1) HK1209161A1 (es)
IL (1) IL234920B (es)
MX (1) MX357392B (es)
SG (2) SG10201608234UA (es)
WO (1) WO2013151577A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358408B (es) 2011-03-02 2018-08-20 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos.
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9449284B2 (en) * 2012-10-04 2016-09-20 Nec Corporation Methods and systems for dependency network analysis using a multitask learning graphical lasso objective function
CN103558354B (zh) 2013-11-15 2015-07-15 南京大学 一种基于生物组学整合技术的水体毒性分析方法
EP3158487A1 (en) * 2014-06-20 2017-04-26 Connecticut Children's Medical Center Automated cell culture system and corresponding methods
CA2960837A1 (en) 2014-09-11 2016-03-17 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
CN105624275B (zh) * 2014-11-06 2020-03-27 上海市东方医院 Eif4g1在鳞癌诊断和治疗中的应用
JP6270221B2 (ja) 2015-02-13 2018-01-31 国立研究開発法人産業技術総合研究所 バイオマーカー探索方法、バイオマーカー探索装置、及びプログラム
KR101786859B1 (ko) * 2015-04-30 2017-10-17 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
ES2878185T3 (es) * 2015-05-28 2021-11-18 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Ensayos para identificar elementos genéticos que afectan al fenotipo
CN106250717B (zh) * 2015-06-04 2019-03-12 徐勇 急性髓性白血病的miRNA与转录因子的系统及其构建方法和应用
US20160363567A1 (en) * 2015-06-15 2016-12-15 Lunatech, Llc Vapor Device For Stressing And Analyzing Compounds
US11061034B2 (en) 2015-10-14 2021-07-13 Public University Corporation Yokohama City University Blood biomarker for use in evaluation of effect of drug therapy on kidney cancer
CN115639134A (zh) 2016-06-10 2023-01-24 加利福尼亚大学董事会 基于图像的细胞分选系统和方法
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
CN106834105A (zh) * 2017-02-21 2017-06-13 齐齐哈尔医学院 一种用于表观遗传分析的设备和方法
US11636917B2 (en) * 2017-06-28 2023-04-25 The Regents Of The University Of California Simulating the metabolic pathway dynamics of an organism
CN107475346B (zh) * 2017-08-11 2021-08-06 北京汉典制药有限公司 一种体外筛选糖尿病肾病药物的方法
JP6902977B2 (ja) * 2017-09-22 2021-07-14 新日本無線株式会社 起動回路の故障検出方法
EP3697925A4 (en) * 2017-10-18 2021-06-23 Venn Biosciences Corporation IDENTIFICATION AND USE OF BIOLOGICAL PARAMETERS FOR DIAGNOSIS AND THERAPY MONITORING
JP2021073432A (ja) * 2018-03-02 2021-05-13 国立研究開発法人医薬基盤・健康・栄養研究所 治療標的である活性化キナーゼのスクリーニング方法
JP7176381B2 (ja) * 2018-12-03 2022-11-22 富士通株式会社 環状分子の構造探索方法、及び構造探索装置、並びにプログラム
CN109536473A (zh) * 2018-12-19 2019-03-29 华中科技大学鄂州工业技术研究院 整合多组学数据推测细胞转分化中关键蛋白质激酶的方法
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US20210080466A1 (en) * 2019-06-26 2021-03-18 Berg Llc Markers for the diagnosis of prostate cancer
JP2023517076A (ja) * 2020-03-10 2023-04-21 エイアイ：オン イノベーションズ、インコーポレイテッド 哺乳類転移学習のためのシステム及び方法
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
CN113138249B (zh) * 2021-04-12 2021-11-23 北京蛋白质组研究中心 基于微孔阵列芯片的微量样本代谢组、蛋白质组和磷酸化蛋白质组多组学分析方法
WO2022240875A1 (en) * 2021-05-13 2022-11-17 Scipher Medicine Corporation Assessing responsiveness to therapy
CN113943720A (zh) * 2021-11-03 2022-01-18 江苏省农业科学院 一种绿盲蝽GRK基因、其dsRNA及其合成方法和应用
WO2023230268A1 (en) * 2022-05-27 2023-11-30 Memorial Sloan-Kettering Cancer Center Systems and methods for metabolite imputation
CN117417914A (zh) * 2022-07-18 2024-01-19 华东师范大学 预防和保护脑缺血疾病的标志物及阿司匹林衍生物在预防和保护脑缺血疾病中的应用
WO2024081740A1 (en) * 2022-10-13 2024-04-18 Somalogic Operating Co., Inc. Systems and methods for validation of proteomic models

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
ATE262374T1 (de) 1991-11-22 2004-04-15 Affymetrix Inc Kombinatorische strategien für polymersynthese
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP1262564A3 (en) 1993-01-07 2004-03-31 Sequenom, Inc. Dna sequencing by mass spectrometry
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
CA2441060A1 (en) * 2001-03-13 2002-09-19 Ashni Naturaceuticals, Inc. Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes
US8000949B2 (en) * 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004021144A2 (en) 2002-08-29 2004-03-11 Gene Network Sciences, Inc. Systems and methods for inferring biological networks
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
JP4288345B2 (ja) 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 新規てんかんモデル動物
EP1512970A1 (en) 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
WO2005035780A1 (ja) * 2003-10-14 2005-04-21 Cellfree Sciences Co.,Ltd. 指標物質の新規スクリーニング方法
WO2005107412A2 (en) 2004-04-30 2005-11-17 Rosetta Inpharmatics Llc Systems and methods for reconstruction gene networks in segregating populations
EP1607898A3 (en) * 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
CA2587765A1 (en) * 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
EP1842147A2 (en) 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Method for modeling cell signaling systems by means of bayesian networks
EP1887351A4 (en) 2005-05-31 2009-04-08 Jcl Bioassay Corp SCREENING METHOD FOR SPECIFIC PROTEIN IN DETAILED PROTEOME ANALYSIS
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2006299079A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
US8571803B2 (en) 2006-11-15 2013-10-29 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
JP2009050171A (ja) * 2007-08-23 2009-03-12 Toyobo Co Ltd 表面プラズモン共鳴による基板上におけるリン酸化の検出方法
EP3156077B1 (en) 2007-12-04 2022-03-09 Arbutus Biopharma Corporation Targeting lipids
PE20120015A1 (es) * 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
CA2743473C (en) * 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
EP2600154A4 (en) 2010-03-31 2014-06-11 Univ Kumamoto Nat Univ Corp METHOD FOR PRODUCING DATA SET FOR INTEGRATED PROTEOMIC, INTEGRATED PROTEASE METHOD USING THE DATA SET FOR INTEGRATED PROTEOME, THAT IS PRODUCED BY THE PRODUCTION METHOD, AND METHOD FOR IDENTIFYING, BY ITS USE, THE SUBSTANCE THAT IN THE ORIGIN
MX358408B (es) * 2011-03-02 2018-08-20 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos.

Also Published As

Publication number Publication date
WO2013151577A9 (en) 2014-11-20
IL234920B (en) 2019-12-31
EA038600B1 (ru) 2021-09-21
AU2012376214A1 (en) 2014-10-30
EA201491833A1 (ru) 2015-01-30
MX2014011797A (es) 2014-12-10
KR102149070B1 (ko) 2020-10-15
CA2869296A1 (en) 2013-10-10
KR20140142357A (ko) 2014-12-11
CN108048521A (zh) 2018-05-18
US20130259847A1 (en) 2013-10-03
AU2019200670B2 (en) 2021-09-23
BR112014024537A2 (pt) 2017-08-08
JP6767320B2 (ja) 2020-10-14
SG11201406201YA (en) 2014-10-30
JP2021003121A (ja) 2021-01-14
AU2019200670A1 (en) 2019-02-21
EP2834366A4 (en) 2016-04-27
CN108048521B (zh) 2022-05-27
NZ718138A (en) 2017-11-24
CN104520435A (zh) 2015-04-15
EP2834366A1 (en) 2015-02-11
IL234920A0 (en) 2014-12-31
JP2018033448A (ja) 2018-03-08
WO2013151577A1 (en) 2013-10-10
HK1209161A1 (en) 2016-03-24
NZ700647A (en) 2016-08-26
JP6189926B2 (ja) 2017-08-30
KR20200105524A (ko) 2020-09-07
SG10201608234UA (en) 2016-11-29
JP2015519876A (ja) 2015-07-16
WO2013151577A8 (en) 2014-12-31
US20190279736A1 (en) 2019-09-12
CN110456035A (zh) 2019-11-15
US10061887B2 (en) 2018-08-28
AU2012376214B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2014011797A (es) Ensayos basados en interrogatorios celulares y uso de los mismos.
SG193006A1 (en) Interrogatory cell-based assays and uses thereof
WO2013176694A8 (en) Interrogatory cell-based assays for identifying drug-induced toxicity markers
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
GB201014805D0 (en) Microfluidics based assay device
BR112012006055A2 (pt) métodos para uso na previsão de produção de areia de um sistema de reservatório geomecânico, para produção de areia de um sistema de reservatório geomecânico, e, para operar um sistema de reservatório geomecânico para controlar produção de areia do sistema de reservatório geomecânico
GB2509036A (en) Providing a network-accessible malware analysis
GB2519906A (en) Methods and systems for detecting biological components
WO2011120006A8 (en) Detection system for droplet-based assays
WO2012024658A3 (en) Integrated analysis system
WO2012047618A3 (en) Mesothelioma biomarkers and uses thereof
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
NZ606725A (en) Methods for predicting anti-cancer response
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EP4219745A3 (en) Spatially encoded biological assays using a microfluidic device
WO2014007308A3 (en) Positioning by a moving communication system
WO2013121342A3 (en) Lighting configuration apparatus and methods utilizing distance sensors
WO2013070756A3 (en) System and method for processing samples
BR112013025758A2 (pt) monitoramento de misturas de amplificação de recombinase polimerase
MX2016000997A (es) Metodos y composiciones para detectar contaminacion bacteriana.
EP2598873A4 (en) BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
FR2964331B1 (fr) Membrane chimiquement stabilisee, son procede de preparation et ses utilisations
GB2492739A (en) Evaluating capability of a system to perform a task by comparing models of the system and the task

Legal Events

Date Code Title Description
FG Grant or registration